Evidence map›Paper›PMID 37939683›Full record

ArticleRespiration; international review of thoracic diseases2023

Impact of Endobronchial Valve Treatment on Lung Function Decline.

Jorine E Hartman, Karin Klooster, T David Koster, Orestes A Carpaij, Marlies van Dijk, Dirk-Jan Slebos

Abstract readNews
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiration; international review of thoracic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jorine E HartmanDepartment of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Karin KloosterDepartment of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
T David KosterDepartment of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Orestes A CarpaijDepartment of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Marlies van DijkDepartment of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Dirk-Jan SlebosDepartment of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEndobronchial valve (EBV) treatment has been shown to be beneficial for patients with severe emphysema. The forced expiratory volume in 1 s (FEV1) was found to be significantly higher compared to baseline for up to 3 years after treatment although the magnitude of improvement gradually decreases over time. So far, it has not been investigated whether this treatment decelerates the decline in lung function. Therefore, our aim was to investigate the lung function decline before and after EBV treatment.

methodsWe included patients who were treated with EBVs in our hospital, of whom pre-treatment spirometry results were available (at least 4 measurements within at least 2 years before treatment) and who had an annual FEV1 measurement up to 3 years after treatment.

resultsIn total, 45 patients were included (73% female, FEV1: 28 ± 7% of predicted, residual volume: 232 ± 32% of predicted) who had a mean pre-treatment FEV1 decline of -64 mL/year. Mean FEV1 "decline" after treatment was +13 mL/year, since FEV1 was still above the baseline level at 3-year follow-up. However, the FEV1 decline between 1 and 3 years of follow-up was not significantly different compared to the pre-treatment decline (-73 mL/year, p = 0.179).

conclusionsOur results show that the EBV treatment does not influence the progression of disease in terms of lung function decline. However, the treatment does improve the FEV1 up to a level that is still comparable 3 years after treatment with the baseline level.

Indexed as

Pulmonary EmphysemaBronchoscopyFemaleForced Expiratory VolumeHumansLungLung Volume MeasurementsMalePneumonectomyTreatment OutcomeBronchoscopic lung volume reductionEmphysemaLung function decline

Identifiers

PMID37939683
PMCPMC10733934

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.